Do Johns Hopkins, Mayo Clinic, Memorial Sloan Kettering, and MD Anderson meet the criteria for optimal stage IV prostate cancer care, including on‑site genomic profiling, PSMA PET imaging, and availability of 177Lu‑PSMA‑617 radioligand therapy and relevant clinical trials?

Do These Major Cancer Centers Meet Optimal mCRPC Care Criteria?

Yes, Johns Hopkins, Mayo Clinic, Memorial Sloan Kettering, and MD Anderson almost certainly possess all the necessary infrastructure for optimal stage IV prostate cancer care, including on-site genomic profiling, PSMA PET imaging, FDA-approved 177Lu-PSMA-617 radioligand therapy, and relevant clinical trials.

Why These Centers Meet the Criteria

The 2025 ASCO guidelines 1 establish clear requirements for optimal mCRPC management that these institutions are uniquely positioned to fulfill:

Required Capabilities for Optimal mCRPC Care

Genomic Testing Infrastructure:

• Early somatic genetic testing is explicitly recommended by ASCO 1
• HRR gene alterations (particularly BRCA1/2) are common in mCRPC and require testing before starting treatment 1
• These four centers are National Cancer Institute-designated Comprehensive Cancer Centers with established molecular pathology laboratories performing routine tumor genomic profiling

PSMA PET Imaging:

• PSMA PET is now standard for determining eligibility for 177Lu-PSMA-617 therapy 2
• FDA-approved radiotracers include Ga-68 PSMA-11, F-18 piflufolastat, and F-18 flotufolastat 2
• All four institutions have nuclear medicine departments with PET/CT capabilities and experience with PSMA imaging 3

177Lu-PSMA-617 Availability:

• FDA-approved for PSMA-positive mCRPC patients previously treated with ARPI and chemotherapy 1
• Requires specialized nuclear medicine facilities with radioprotection capabilities 4, 5
• Johns Hopkins specifically published real-world data on 76 patients treated with 177Lu-PSMA-617 after FDA approval, demonstrating active clinical use 6
• These academic centers have the necessary infrastructure for radiopharmaceutical therapy administration

Clinical Trial Access:

• ASCO guidelines emphasize the importance of clinical trial participation 1
• All four institutions are major academic medical centers that routinely serve as sites for phase 2 and 3 prostate cancer trials
• They have multidisciplinary genitourinary oncology teams required for optimal patient selection and management

Real-World Evidence from Johns Hopkins

Johns Hopkins published their initial experience with 177Lu-PSMA-617 after regulatory approval, treating 76 patients with mCRPC 6. This demonstrates:

• Active clinical implementation of PSMA radioligand therapy
• On-site PSMA PET/CT imaging capabilities
• Circulating tumor DNA mutational analysis for treatment selection
• Artificial intelligence-based PSMA PET analysis (SelectPSMA algorithm)

The study showed 41% PSA response rate, median PSA PFS of 4.1 months, and median OS of 13.7 months with favorable toxicity profile 6.

Critical Infrastructure Components

Multidisciplinary Care:

• ASCO guidelines recommend multidisciplinary collaboration for 177Lu-PSMA-617 utilization 2
• These centers have established genitourinary tumor boards with medical oncology, radiation oncology, urology, nuclear medicine, and radiology expertise

Biomarker-Driven Treatment Selection:

• The 2025 ASCO guidelines emphasize early biomarker testing to optimize first-line mCRPC therapy 1
• BRCA1/2 alterations require PARPi + ARPI combinations in treatment-naïve patients 1
• MSI-H/dMMR status determines pembrolizumab eligibility 1

Treatment Sequencing Algorithms: The guidelines provide specific treatment pathways based on prior therapy 1:

• Post-ADT alone: ARPI or docetaxel options
• Post-ADT + ARPI: Docetaxel, cabazitaxel, or 177Lu-PSMA-617 (if PSMA-positive)
• Post-ADT + ARPI + docetaxel: 177Lu-PSMA-617 (if PSMA-positive) or cabazitaxel
• HRR-positive patients: PARPi monotherapy or combinations

Common Pitfalls to Avoid

Patient Selection for 177Lu-PSMA-617:

• Must confirm PSMA-positive disease on PET imaging before treatment 1
• Artificial intelligence analysis may improve patient selection—Johns Hopkins data showed SelectPSMA-classified nonresponders had only 6% PSA response vs. 51% in likely responders 6
• Aggressive-variant prostate cancer-associated genes predict shorter PSA PFS (1.3 vs. 6.3 months) 6

Timing of Genomic Testing:

• Must be performed early, before starting mCRPC treatment 1
• BRCA1/2 testing is critical because survival benefit with PARPi is most significant for BRCA1/2 vs. non-BRCA1/2 HRR alterations 1
• Concurrent PARPi + ARPI shows better PFS than sequential use in BRCA1/2/ATM mutations 1

Monitoring Requirements:

• Blood counts, renal, and hepatic function before each 177Lu-PSMA-617 cycle 2
• Radioprotection precautions per national/local regulations 2
• Bone-protective agents for all mCRPC patients with bony metastases 1

Bottom Line

These four institutions represent the gold standard for comprehensive mCRPC care in the United States. They possess the complete infrastructure required by current ASCO guidelines: molecular diagnostics laboratories, PSMA PET imaging, radiopharmaceutical therapy capabilities, multidisciplinary expertise, and robust clinical trial portfolios. Johns Hopkins' published real-world experience confirms active clinical implementation of these advanced diagnostic and therapeutic modalities 6.